She's slower than her colleagues. Always the last to leave meetings. Takes forever to finish tasks.
Then you ask the right question: "Do you have any repetitive behaviors or thoughts that feel hard to control?"
Suddenly, everything clicks.

GLP-1 agonists may get the spotlight—but they’re not the only option. Many patients can’t afford them, don’t want the side effects, or prefer to stick with psychiatric meds they already know.

TD affects ~2.6 million people in the U.S., but only 40,000 are being treated.

I just read a Lilly-sponsored CME on Medscape featuring Dr. Malaz Boustani—a respected geriatrician doing critical work with underserved communities. But this isn't just education—it's marketing for Lilly’s anti-amyloid drug Donabemab.

At Carlat Publishing, we regularly debate trends in psychiatry—and neurodivergence is one of today’s most charged topics.
Let’s call it opinion divergence: Some on our team feel that the DSM-5 term “autism spectrum disorder” is politically insensitive. Others see it as clinically essential.

"The only thing that works for me is Xanax." "Can I get a 3-month script for Klonopin? My last doc didn't mind."
We’ve all heard versions of these.

This week, the FDA cleared the first blood test for Alzheimer’s disease: the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio.It sounds like a big step forward. Maybe it will prove to be one. But after 22 years of Carlat Report coverage of overhyped tests and treatments, I’ve learned to pause before celebrating “firsts.”

ADHD pharmacology can feel overwhelming. Dozens of formulations. Conflicting data. High stakes for outcomes—and side effects. Each chapter of our Medication Fact Book starts with general tips, and I’m revising the ADHD section for our 8th edition.